PerkinElmer (NYSE:PKI) has closed its $1.3 billion deal to buy Euroimmun Medical Laboratory Diagnostics, the scientific instrument-maker reported today. The acquisition, first announced in June, involves Euroimmun’s 2,400 employees and autoimmune testing solutions. The move helps to expand PerkinElmer’s footprint in autoimmune and allergy diagnostic markets. Get the full story at our sister site, Drug Delivery Business News.
PerkinElmer (NYSE:PKI) inked a deal today to acquire Euroimmun Medical Laboratory Diagnostics for $1.3 billion in cash. The move is an effort to expand into autoimmune and allergy diagnostic markets, according to the scientific instruments-maker. Germany-based Euroimmun has 2,400 employees and is expected to bring in $310 million in revenue this year. Get the full […]